Noteworthy, PARP inhibitors, the first molecularly targeted anti-cancer drugs that exploit the DNA repair defect present in BRCA1- or BRCA2-mutant cancers were FDA-approved at the end of 2014. The gene discussed is BRCA1; the disease is cancer.